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Abstract
Cancer of the stomach is among the leading causes of death
from cancer worldwide. The transcription factor C/EBPβ is
frequently overexpressed in gastric cancer and associated with
the suppression of the differentiation marker TFF1. We show
that the murine C/EBPβ knockout stomach displays unbalanced
homeostasis and reduced cell proliferation and that tumorigenesis
of human gastric cancer xenograft is inhibited by knockdown of
C/EBPβ. Cross-species comparison of gene expression profiles
between C/EBPβ-deficient murine stomach and human gastric
cancer revealed a subset of tumors with a C/EBPβ signature.
Within this signature, the RUNX1t1 tumor suppressor transcript
was down-regulated in 38 % of gastric tumor samples. The
RUNX1t1 promoterwas frequently hypermethylated and ectopic
expression of RUNX1t1 in gastric cancer cells inhibited prolif-
eration and enhanced TFF1 expression. These data suggest that
the tumor suppressor activity of both RUNX1t1 and TFF1 are
mechanistically connected to C/EBPβ and that cross-regulation
between C/EBPβ-RUNX1t1-TFF1 plays an important role in
gastric carcinogenesis.
Key message
& C/EBPβ controls proliferation and differentiation balance
in the stomach.
& Homeostatic differentiation/proliferation balance is al-
tered in gastric cancer.
& RUNX1t1 is a C/EBPβ-associated tumor suppressor.
& RUNX1t1 negatively regulates C/EBPβ pro-oncogenic
functions.
Keywords C/EBPβ . RUNX1t1 . Gastric cancer . TFF1 .
Proliferation . Homeostasis
Introduction
Gastric cancer is one of the leading causes of cancer-related death
in the developingworld [1]. The oncogenic transformation of the
gastric mucosa is often linked to persistent injury caused by
chronic infection with Helicobacter pylori and chronic inflam-
mation coincides with gastric cancer development [2]. The ma-
jority of sporadic gastric tumors belong to the intestinal type of
gastric cancer, a histological entity characterized by expansive
growth that retains a glandular structure. Despite the histological
coherence however, no central common molecular pathway has
been convincingly shown as aberrantly regulated in intestinal-
type gastric cancer development. This is in contrast to another
type of stomach cancer coined diffuse-type gastric cancer
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that is characterized by scattered growth and associated
with loss of the adhesion protein E-cadherin [3–5].
Among the known common molecular changes in
intestinal-type gastric cancer are enhanced expression of
cyclooxygenase-2 (COX2) and diminished expression of
the mucous-associated protein trefoil factor 1 (TFF1).
Altered expression of both proteins is associated with can-
cer progression, although no recurrent mutations have
been described [6–9]. Nevertheless, TFF1 knockout and
COX2-overexpressing mice develop gastric tumors,
highlighting the importance of the abnormal expression
of these proteins for cancer development [10, 11].
Interestingly, CCAAT enhancer binding protein β
(C/EBPβ) is also frequently overexpressed in intestinal-
type gastric cancer and associated with both enhanced
COX2 expression and loss of TFF1 [12, 13].
C/EBPβ is a transcription factor that belongs to the
C/EBP family. C/EBPβ plays a central role in cell differ-
entiation and cell lineage definition, as well as in inflam-
mation control [14]. C/EBPβ has been implied to play a
pro-oncogenic role in several other types of cancer, in-
cluding mammary, skin, intestinal, and bladder cancer,
as well as in acute myeloid leukemia (AML) and lympho-
ma [15–20]. C/EBPβ is thought to shield from apoptosis
and to promote cell proliferation through several mecha-
nisms, most notably in conjunction with cyclin D1 [14,
21–23]. Although C/EBPβ has not been reported as fre-
quently mutated in tumorigenesis, signaling pathways reg-
ulating its activity and expression of its isoforms may
account for a pro-oncogenic function of C/EBPβ [14,
24]. In gastric cancer, it is possible that C/EBPβ activa-
tion represents an upstream event with broader implica-
tions to tumorigenesis, of which TFF1 down-regulation
and COX2 overexpression are hallmarks. Thus, a deeper
insight into the role of C/EBPβ in normal and oncogenic
stomach biology may help unraveling novel molecular
candidates in gastric cancer development.
Here, we examined the functions of C/EBPβ in the murine
stomach. Our results show that C/EBPβ controls the balance
between proliferation and differentiation in the murine stom-
ach. Cross-species analysis of gene expression between
mouse C/EBPβKO stomachs and human gastric cancer iden-
tified a C/EBPβ regulated gene signature in a subgroup of
intestinal-type tumors. Within this signature, repression
of RUNX1t1 stood out as a potential tumor suppressor
event. Ectopic expression of RUNX1t1 reduced prolifer-
ation in gastric cancer cell lines and counteracted the
repression of TFF1 by C/EBPβ. The RUNX1t1 promot-
er was found to be frequently hypermethylated in hu-
man gastric cancer cases. Our data suggest C/EBPβ
activation and RUNX1t1 silencing as important events
in the process of gastric carcinogenesis and suggests
cross-regulation of C/EBPβ, TFF1, and RUNX1t1.
Methods
Human gastric cancer samples and microarray data
Human tissue samples were derived from patients that had
undergone resection for sporadic gastric adenocarcinoma at
the Robert-Roessle Clinic (1995–2003). The selection of sam-
ples, the procedure for histological classification and staging,
the second blinded evaluation by an independent pathologist
including assessment of tumor content in the pieces that RNA
was extracted from as well as RNA extraction, and microarray
procedure have been described elsewhere [25].
Transgenic mice
C/EBPβ knockout (KO) animals were previously established
in C57-Bl6 background [26]. Animals were bred and kept
according to the institutional guidelines, and genotyped by
PCR as previously described [26, 27].
C/EBPβ knockdown cells and in vivo tumorigenic assay
MKN74 cells were infected with lentivirus containing GFP-
tagged control shRNA and shRNA against C/EBPβ.
Efficiency of knockdown was assessed by Western blot and
proliferation was measured by BrdU incorporation assay. The
effect of C/EBPβ expression on tumor formation was exam-
ined by subcutaneously implanting 3×106 cells of both con-
trol MKN74 and ShRNA-mediated C/EBPβ-silenced
MKN74 into 6–8-week-old male NIH(s) II-nu/nu nude mice,
four mice per group. The animals were monitored weekly for
tumor formation for 20 days after inoculation. Tumor sizes in
two dimensions were measured with calipers, and volumes
were calculated with the formula (a×b2)×0.5, wherein “a”
is the long axis and “b” is the short axis (in millimeters). Mice
were maintained and sacrificed according to institutional
guidelines, and at termination of the experiment tumors were
excised, fixed, embedded, and analyzed by immunohisto-
chemistry for Ki67 and C/EBPβ expression.
Co-immunoprecipitation
Flag-tagged RUNX1t1 was expressed in MKN28 and
MKN45 cell lines. Cells were harvested and lysed in buffer
containing 50 mM Tris pH 8, 1 mM EDTA, 150 mM NaCl,
0.2 % NP-40, 5 mM MgCl2, 50 μM ZnCl2, and protease
inhibitor cocktail (Roche®). Protein lysates were incubated
at 4 °C with Protein A sepharose beads (Sigma®) for 1 h.
Beads were then washed four times in lysis buffer and exam-
ined by Western blot analysis.
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Chromatin immunoprecipitation
Stomachs from two wild-type C57-Bl6 mice were excised,
washed in ice-cold PBS, and incubated for 2 h in 30 mM
EDTA. Epithelial cells were scrapped from the muscle layer
and resuspended in 4 % paraformaldehyde for fixing and
protein-DNA crosslinking. Cells were washed and resuspend-
ed in hypotonic buffer (2.5 mM Hepes, 1.5 mM MgCl2,
10 mM KCl, 0.1 % NP-40, 1 mM DTT, 0.5 mM PMSF) and
incubated 10 min on ice for nuclei extraction. Nuclei were
then resuspended in sonication buffer (50 mM Hepes,
140 mM NaCl, 1 mM EDTA, 1 % Triton X-100, 0.1 % Na-
deoxycholate, 0.1 % SDS, 0.5 mM PMSF), incubated for
30 min, and sonified until 200–1000 bp fragments were ob-
tained. Sonified chromatin was then immunoprecipitated with
anti-C/EBPβ antibody (sc-150 Santa-Cruz Biotechnology®),
or appropriate IgG control overnight at 4 °C, and 2 h incuba-
tion with Protein A Sepharose Beads (Sigma®). Beads were
then washed in sonication buffer and TE buffer, and DNA eluted
in elution buffer (50 mM Tris, pH 8.0, 1 mM SDS, 50 mM
NaHCO3). DNAwas de-crosslinked overnight at 65 °C and iso-
lated by standard phenol/chloroform procedure. Binding of
C/EBPβ to the TFF1 promoter was assessed by PCR (5′-
gaaggtcatgtcaagggaggt-3′; 5′-atgagcttgcaccacgttct-3′). The pro-
moter of the MUC5Ac was used as a negative control (5′-
ctgtggagcatggggaaat-3′; 5′- gaaccacagacctgctccac-3′).
Immunohistochemistry
Stomachs were obtained from 3-month-old C/EBPβ knockout
(KO) mice animals. Stomachs were longitudinally excised,
formalin-fixed, and embedded in paraffin. Gastric cancer tis-
sue microarrays were obtained as described elsewhere [28].
Serial sections were obtained, deparaffinized, stained with
hematoxylin and eosin, and examined by a pathologist. An
additional group of sections were treated with 10 mM citrate
buffer and stained with 1:100 anti-Ki67 (MIB1 DAKO),
1:500 anti-C/EBPβ,1:50 anti-TFF1 (sc-150 and sc-517213
Santa Cruz Biotechnology), or 1:500 anti-RUNX1t1
(SAB2102065 Sigma®) antibody. After washing with PBS
with 0.02 % Tween and incubation with horseradish
peroxidase-bound secondary antibody (GE Healthcare®), de-
velopment was performed using di-amido-benzidine.
BrdU assay
Cells with stable C/EBPβ knockdown were sorted and plated
to 40 % confluence. Cells were also transfected with
RUNX1t1 and analyzed for BrdU incorporation after 48 h.
Briefly, cells were incubated with 1 M Bromo-deoxy-uridine
for 20min and then trypsinized and harvested in ice-cold PBS.
Cells were then fixed, permeabilized, and stained with fluo-
rescent anti-BrdU antibody according to the APC-BrdU flow
kit protocol (BD Biosciences®). Dead cells were stained with
7-AAD and BrdU-positivity was then assessed by flow
cytometry.
Electrophoretic mobility shift assay (EMSA)
MKN28 and MKN45 cells were transfected with increasing
amounts of RUNX1t1. Nuclear extracts were prepared from
transfected cells, quantified, and incubated with radioactively
labeled (32P) palindromic C/EBPβ binding oligonucleotide.
EMSA was performed as previously described [29]. Anti-C/
EBPβ antibody (sc-150 Santa-Cruz Biotechnology®) was
added to super-shift samples and competition with 50-fold
excess of unlabeled oligonucleotide to confirm specificity.
Total RNA extraction, cDNA synthesis, and quantitative
real-time PCR
For RNA extraction frommouse tissue, stomach sections were
frozen in liquid nitrogen after excision and finely ground in a
mortar. For RNA extraction from gastric cancer cells, these
were harvested in ice-cold PBS and pelleted at 2000 rpm.
Lysis buffer was then added to the obtained powder or to the
pellet which was then vigorously resuspended using a 3-ml
syringe. RNAwas extracted using a universal RNA extraction
kit (Roboklon®). RNAwas quantified, cDNA synthesized by
standard methods, and SYBER green quantitative real-time
PCR performed (see Supplementary Table 4 for primer
sequences).
Plasmids
For the construction of C/EBPβ isoform expression vectors,
LAP*, LAP, and LIP were cloned from human cDNA by
PCR, following digestion with restriction enzymes, ligation
into pcDNA3-flagged plasmid, and ampicillin selection.
RUNX1t1 expression plasmid (pCMV-3xFlag-ETO) was ob-
tained from ADDGENE® (ref: #12507). TFF1-luciferase re-
porter plasmid was similarly cloned from human cDNA into a
pGL3-basic plasmid. For the construction of C/EBPβ knock-
down vectors, shRNA (5′-gccgcgacaaggccaagatgc-3′) was
inserted into a pLVTH-M lentivral vector.
Tissue culture, transfection, and luciferase assay
MKN28, MKN45, and MKN74 cell lines were grown in
RPMI medium (Gibco®). For transfection, cells were
trypsinized, seeded, and grown to 50–60 % confluence.
C/EBPβ isoform plasmids and/or RUNX1t1 plasmid were
resuspended in serum-free medium with transIT (Myrus®)
transfection reagent and added to the cells. Protein and RNA
were extracted after 48 h and analyzed by Western blot and
real-time PCR. For Luciferase assay, expression plasmids
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were co-transfected with TFF1-luciferase reporter plasmid
and normalization MCV-Renilla plasmid. After 48 h, cells
were lysed and reporter activity measured in a luminometer.
Results were presented as a Luciferase/renilla activity ratio.
RUNX1T1 promoter methylation analysis
Methylation analysis of the RUNX1t1 promoter was deter-
mined by methylation-specific PCR (MSP), as previously de-
scribed [30]. MSP method distinguishes unmethylated from
methylated alleles in a given gene based on sequence changes
produced after bisulfite treatment of DNA, which converts
unmethylated but not methylated cytosines to uracil.
Subsequently, PCR using primers specific to either methylated
or unmethylated DNA was performed. Genomic DNA
(350 ng) was bisulfite-treated and purified with EZ DNA
Methylation Kit Gold (Zymo Research, CA, USA®). The
primer sequences of RUNX1t1, for both methylated and
unmethylated reactions, were as previously described [30].
One hundred nanograms of bisulfite-modified DNAwas used
in each PCR. Amplification was carried out for 36 cycles (30 s
at 95 °C, 30 s at 56 °C, and then 30 s at 72 °C). Control PCRs
lacking genomic DNA were performed for each set of reac-
tions. Amplified products were separated by electrophoresis in
a 2.5 % agarose gel.
Bioinformatic microarray data analysis and statistical
analysis
The raw data files (.text files for murine Agilent Technologies®
arrays and .cel files for human Affymetrix GeneChips®) were
imported into GeneSpring GX 12.1 software (Agilent
Technologies®) as two separate species-specific experiments.
All subsequent microarray data analyses were performed using
this software. Preprocessing (background correction, normaliza-
tion, and probe summarization) was performed according to the
RMA algorithm followed by baseline transformation to the me-
dian of all samples (in one experiment). Quality control was done
by assessment of inter-array correlation analysis calculating the
correlation coefficient of each array to every other one. By this
means, one array of the murine gene expression experiment was
identified to show relatively weak correlation tomost of the other
samples and thus excluded from further analysis. The human
arrays yielded correlation coefficients between 0.829 and
0.972, with an arithmetic mean of 0.917 and the murine arrays
between 0.991 and 0.924 with a mean of 0.9. In the murine array
experiment, only probes owning “detected” flags in at least three
arrays (34,150 probes) were used for further analyses. Genes
whose expression between groups of samples was significantly
different were identified by Welch test with p≤0.01 being the
significance cutoff. The fold change (FC) of expression between
groups was calculated as the fold difference between group
means. Gene annotation information was obtained from
GeneSpring GX software (state of 08/2012). For hierarchical
clustering, “Euclidean distance” and “complete linkage” were
used as distance metric and linkage algorithm. The migration
of genes between the murine and human microarray experiment
was performed using the Orthology Search Tool of bioDBnet
athttp://biodbnet.abcc.ncifcrf.gov/.
Results
C/EBPβ knockdown reduces the tumorigenic potential
of gastric cancer cells
Enhanced C/EBPβ expressionmainly in the human intestinal-
type gastric cancer subtype has previously been observed [12,
13]. The functional importance of high C/EBPβ expression in
gastric cancer was examined by stable knockdown in a human
gastric cancer cell line using a viral-based GFP-tagged short
hairpin RNA. C/EBPβ knockdown efficiency in MKN74 was
approximately 70%, as confirmed by protein immunoblotting
(Fig. 1a). Proliferation was examined by BrdU incorporation
and, as shown in Fig. 1b, proliferation was reduced after
C/EBPβ knockdown. C/EBPβ has previously been reported
to repress the gastric differentiation marker and tumor sup-
pressor TFF1 [31, 32], and in accordance with these data,
C/EBPβ knockdown enhanced TFF1 expression in MKN74
(Fig. 1c).
The tumorigenic potential of MKN74 before and after
C/EBPβ knockdown was compared by xeno-transplantation
in immune-compromised mice, as shown in Fig. 1d. Twenty
days post-injection, C/EBPβ knockdown cells formed mark-
edly smaller tumors than parental cells, with less weight and
volume (Fig. 1c). Ki67 staining showed reduction of cell pro-
liferation in tumors originating from C/EBPβ knockdown
cells in comparison to controls (Fig. 1d). Interestingly, re-
expression of C/EBPβ was accompanied by proliferation in
tumors. Consistently, knockdown cells in tissue culture re-
quired frequent sorting to prevent overgrowth of cells that
regained C/EBPβ expression, suggesting selection for
C/EBPβ re-expression as a growth advantage for gastric tu-
mor cells. Taken together, these results suggest that C/EBPβ
plays an important role in gastric cancer cell proliferation.
C/EBPβ knockout mice display imbalanced
differentiation/proliferation of the gastric mucosa
Analysis of nullizygous C/EBPβ stomachs (n=5) revealed a
significant (p<0.001) reduction in the thickness of the antral
gastric mucosa and diminished numbers of Ki67-positive
cells, as compared to the wildtype (WT) (n=8). No other
histological abnormalities were observed and the corpus re-
gion from knockout animals was largely indistinguishable
from theWT. To gain further insight into the causes of reduced
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mucosal thickness, expression of cell cycle-related genes was
examined. As shown in Fig. 2c, reduction of Ki67 and of
proliferating cell nuclear antigen (PCNA) in the KO antral
mucosa was evident by quantitative PCR (qPCR) in accor-
dance with histological observations. Furthermore, expression
of the CDK inhibitor p15 was increased and expression of
cyclin A1, cyclin D3, and cyclin E1 were reduced.
Similarly to human gastric mucosa, TFF1 was not
expressed in proliferating cells of the neck zone in murine
WT gastric epithelium, and expression of C/EBPβ and
TFF1 was found to be mutually exclusive (Fig. 2b). Real-
time PCR confirmed the increased expression of TFF1 in
C/EBPβ KO mucosa (Fig. 2c). Chromatin immunoprecipita-
tion (ChIP) with anti-C/EBPβ antibody in disaggregated mu-
rine stomach epithelial cells showed that C/EBPβ binds to the
promoter of TFF1 in vivo (Fig. 2c). Taken together, the data
suggest a role of C/EBPβ-mediated repression of gastric dif-
ferentiation in proliferating cells of the normal gastric mucosa.
Cross-species gene expression profiling reveals a subset
of intestinal-type gastric tumors with a C/EBPβ regulated
signature
The apparent similarities between human and murine gas-
tric C/EBPβ biology raised the question whether the ho-
meostatic and oncogenic C/EBPβ-dependent proliferation
share common molecular mechanisms. We therefore com-
pared the gene expression profiles derived from C/EBPβ
KO mice with previously analyzed human gastric adeno-
carcinoma samples. These samples were isolated under
the supervision of a pathologist, and areas enriched for
epithelial tumor cells were selected [25].
Differentially expressed genes between the C/EBPβ KO
(n=5) and WT (n=4) mice were identified by Welch test.
Significance in differential expression was accepted at p≤0.01
and a FC of larger than >1.5. These cutoff criteria yielded 171/25
annotated/non-annotated unique transcripts (represented in 233
probes) as up-regulated in the C/EBPβKO and 79/12 annotated/
non-annotated unique transcripts (represented in 135 probes) as
down-regulated (Supplementary Tables 1 and 2 show the 20
most significantly regulated genes).
Next, the combined list of up- and down-regulated
genes (FC > 1.5, p ≤ 0.01) derived from the murine
C/EBPβ KO profiling data was used to cluster data ob-
tained from human gastric cancer microarrays. The
resulting gene expression heatmap revealed a group of
genes that showed explicit regulation (indicated by dark
bluish/reddish spots in the heatmap) across the human
cancer samples (Supplementary Fig. 1, C/EBPβ regulated
gene cluster, indicated by box), among a majority of
genes that did not show any overt deregulation (whitish
spots in heatmap). Genes contained in the strongly regu-
lated subset were then used alone to re-cluster all human
cancer samples. The resultant dendrogram and expression
heatmap (Fig. 3a) revealed a group of cancer samples
(Fig. 3a, black box) that exhibit down-regulation of the
majority of these genes. The group consisted of 16 of
the original 59 (≈27 %) samples and contained primarily
cancers of the intestinal histological type. Importantly,
most of the down-regulated genes in this cancer
Fig. 1 C/EBPβ controls gastric cancer cell proliferation. a Stable
knockdown (KO) of C/EBPβ in MKN74 cell line evaluated by protein
blotting. b Cell proliferation was determined by BrdU analysis. Cells
were labeled with BrdU and incorporation was determined by flow
cytometry (FACS) and plotted against 7-AAD-positive cells, as a
measure of DNA content. c Expression of the gastric differentiation
marker TFF1 was assessed on the stably transfected cells. Expression
was increased in MKN74. d Equal amounts of control and stable
C/EBPβ KO MKN74 cells were injected into nude mice and tumor
volume and weight was assessed at different time points. Tumors
originated from C/EBPβ KO cells were smaller than tumors in the
controls. e Ki67 staining revealed reduction of proliferation in the KO-
derived tumors. All bar graphs represent the result of at least three
independent measurements; asterisk indicates p< 0.05
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subgroup are up-regulated in the C/EBPβ KO gastric
mucosa (changes ranging from 1.5- to 2.3-fold;
Table 1), clearly identifying them as C/EBPβ repressed
genes.
In order to validate the results obtained by microar-
ray comparison, we selected three C/EBPβ repressed
genes, FOG2, SPARCL1, and RUNX1t1, and analyzed
their expression by qPCR. Examination of WT and
C/EBPβ KO stomach confirmed up-regulation of these
genes in the gastric mucosa of C/EBPβ KO mice (five
animals/group; Supplementary Fig. 2A). It was also im-
portant to examine the expression of FOG2, SPARCL1,
and RUNX1t1 in normal human gastric mucosa, as no
matching normal tissue samples were available from the
initial human gastric cancer microarray analysis [25]. As
shown in Supplementary Fig. 2B, expression of all three
genes was down-regulated in intestinal-type gastric can-
cer in comparison to normal tissue; however, a subset of
diffuse-type tumors overexpressed RUNX1t1, compliant
with a different etiology of these tumors. The microar-
ray data-derived expression of C/EBPβ and RUNX1t1
in all analyzed 59 human gastric cancer samples is
depicted in Supplementary Fig. 3.
RUNX1t1 plays a tumor suppressive role in human gastric
cancer and modulates C/EBPβ activity
A connection between RUNX1t1 and C/EBPβ has previously
been suggested to control the proliferative clonal expansion
phase in adipogenesis [33]. Indeed, the C/EBPβ KO stomach
has markedly increased levels of RUNX1t1, and ectopic ex-
pression of C/EBPβ isoforms (LAP*, LAP, and LIP) in
MKN28 and MKN45 cell lines inhibited RUNX1t1 expres-
sion (Fig. 3b), suggesting C/EBPβ mediated repression of
RUNX1t1.
Expression of RUNX1t1 protein was evaluated by tissue mi-
croarray immunohistochemistry on 64 human gastric cancer
samples. Nuclear staining was classified as strong, moderate,
weak, or absent, referencing to RUNX1t1 expression in the nor-
mal mucosa (classified as moderate). As shown in Fig. 4a, 25 out
of 64 (38 %) tumor samples showed weak or absent RUNX1t1
protein staining. To further assess the connection between
C/EBPβ and down-regulation of RUNX1t1 in gastric tumors,
we selected tumor-RNAs showing reduced levels of RUNX1t1.
In 3 out of 10 cases, we found a convincing inverse correlation
between low RUNX1t1 and high C/EBPβ expression (Fig. 4b);
however, the data may also suggest alternative routes of
Fig. 2 Analysis of the gastric phenotype of the C/EBPβ knockout (KO)
mouse. a Quantification of the C/EBPβ KO mice and WT antral gastric
mucosa thickness (in arbitrary units). Adjacent immunohistochemical
panel depicts the reduction of Ki67-positive cells in the C/EBPβ KO
mucosa. Lower panels show qPCR evaluation of Ki67, PCNA, Cyclin
A1, D3, E1, and p15 in the gastric mucosa ofWTandC/EBPβKOmouse
stomach (five animals/group, 3 months old). Expression values were first
normalized to GAPDH expression and values are presented as fold ofWT
expression. bMutually exclusive expression of TFF1 and C/EBPβ in the
normal human (upper panel) and mouse (lower panel) stomach
epithelium; C/EBPβ is expressed in proliferative cells of the neck zone
and TFF1 in differentiated mucous epithelium. c Increased expression of
mRNA of differentiation protein TFF1, in the C/EBPβ KO mouse
mucosa as measured by qPCR. Lower panel show ChIP assay on
disaggregated wt mouse stomach cells, showing in vivo binding of
C/EBPβ to the TFF1 promoter both on an agarose gel (left) and by
qPCR quantification. Results are presented as ratio to anti-IgG control
binding. Binding to the Muc5ac promoter was used as a negative control.
All bar graphs represent the result of at least three independent
measurements; asterisk indicates p < 0.005
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RUNX1t1 down-regulation in gastric cancer. Sequencing of
RUNX1t1 from 26 gastric cancer patients failed to disclose mu-
tations that would explain loss of RUNX1t1 protein (data not
shown); however, analysis of the RUNX1t1 promoter revealed
hypermethylation in 10 out of 20 gastric cancer DNA samples
(Fig. 4c).
In order to determine whether RUNX1t1 down-regulation
in gastric cancer cells has functional consequences on cell
a
b
Fig. 3 a Cross-species comparison of gene expression. Two-way
hierarchical clustering was performed on the human gastric cancer
samples using a strongly regulated gene cluster (shown in
Supplementary Fig. 2) from microarray-derived genes that differed
between murine C/EBPβ KO and WT stomach (p ≤ 0.01, FC ≥ 1.5).
Depicted are the resultant gene and sample dendrograms and the
corresponding expression intensity heatmap. The black box indicates a
tumor cluster in which most of the genes show down-regulation (bluish
spots). This tumor group consisted of 16 of the original 59 (≈27 %)
samples and contained primarily cancers of the intestinal histological
type. b Transfection of C/EBPβ isoforms LAP*, LAP, and LIP into
gastric cell lines MKN28 and MKN45 repressed RUNX1t1 expression
as measured by quantitative PCR. All bar graphs represent the result of at
least three independent measurements; asterisk indicates p< 0.001
Table 1 Genes from the C/EBPβ-clustered intestinal-type gastric cancer genes, showing their regulation in both intestinal-type tumors and C/EBPβ
KO stomachs. Down-regulated genes in intestinal-type gastric cancer are up-regulated in the C/EBPβ KO stomach
Gene name p Regulated in FC p Regulated in FC
(int. vs. diff.) intestinal (C/EBPβKO vs. WT) C/EBPβ
GC KO
COL4A6 Collagen, type IV, alpha 6 0.026065 Down 2.2 0.003434 Up 1.8
COX7A1 Cytochrome c oxidase, 1.34E−07 Down 2.6 0.008941 Up 2.2
Subunit VIIa 1
CPE Carboxypeptidase E 8.69E−04 Down 2 8.96E−04 Up 1.6
GLI1 GLI-Kruppel family member GLI1 3.39E−05 Down 1.9 0.001579 Up 1.6
HLF Hepatic leukemia factor 9.51E−04 Down 2.3 0.007635 Up 1.6
MAMDC2 MAM domain containing 2 1.44E−06 Down 6.2 0.007404 Up 2.3
PDZRN4 PDZ domain containing RING finger 4 0.005077 Down 2.9 0.007338 Up 2
PTCHD1 Patched domain containing 1 0.020572 Down 2.1 0.00189 Up 1.5
PTGER3 Prostaglandin E receptor 3 1.89E−07 Down 3.7 0.004076 Up 1.6
(subtype EP3)
RAI2 Retinoic acid induced 2 6.97E−05 Down 2.6 0.008717 Up 1.6
RUNX1T1 runt-related transcription factor 1;
translocated to, 1 (cyclin D-related)
1.32E−08 Down 5.2 0.00741 Up 1.5
SPARCL1 SPARC-like 1 9.97E−10 Down 2.7 0.007544 Up 1.5
ZFMP2/FOG2 Zinc finger protein, multitype 2 9.81E−08 Down 4.4 0.001298 Up 1.6
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multiplication, we rescued RUNX1t1 expression and evaluat-
ed proliferation by BrdU incorporation. As shown in Fig. 4d,
FACS analysis of BrdU-positive cells showed that re-
expression of RUNX1t1 led to a significant decrease in cell
proliferation.
RUNX1T1 interacts withC/EBPβ to abolish DNAbinding
and TFF1 promoter repression in stomach cells
Immunohistochemical analysis of normal human stomach
showed that RUNX1t1 and C/EBPβ co-localize to the prolif-
erative neck zone of the normal gastric mucosa (Fig. 5a). In
order to analyze if co-expression also entails physical
interaction, we expressed Flag-tagged RUNX1t1 in MKN28
and MKN45 cell lines, where basal RUNX1t1 expression is
very low. As shown in Fig. 5b, all endogenously expressed
C/EBPβ isoforms in both gastric cancer cell lines were co-
precipitated with RUNX1t1.
Previously it had been shown that RUNX1t1 inhibits the
DNA binding of C/EBPβ in pre-adipocytes [33]. EMSAwith
nuclear extracts fromMKN28 and MKN45 gastric cancer cell
lines transfected with increasing amounts of RUNX1t1
showed that RUNX1t1 caused a dose-dependent decrease of
C/EBPβ binding to its DNA consensus sequence. RUNX1t1
did not significantly alter nuclear C/EBPβ expression levels
(Fig. 5c). As C/EBPβ represses TFF1 expression, RUNX1t1
Fig. 4 RUNX1t1 and gastric cancer. a RUNX1t1 expression was
evaluated by immunohistochemistry in 64 human gastric cancer
samples, and staining was classified by comparison to the expression in
the normal mucosa (left panel). Thirty-eight percent of the cases showed
reduced expression of nuclear RUNX1t1 (Tumor 1–3) in comparison to
staining in the normal epithelium. b In 10 gastric tumors with reduced
RUNX1t1, RNA levels were examined for C/EBPβ expression by qPCR.
Only 3 out of 10 cases showed higher C/EBPβ expression as compared to
WT. c The methylation status of the RUNX1t1 promoter was evaluated
by methylation-specific PCR. Bisulfite treatment of tumor DNA converts
unmethylated but not methylated cytosines to uracil, and subsequent
methylation-specific PCR detects either methylated (M) or
unmethylated (U) DNA. Fifty percent of the analyzed human gastric
cancer cases (rows a-b, columns 1–5) present RUNX1t1 promoter
hypermethylation. An increase in the methylation status is considered
when the PCR product with methylation-specific primers is more
intense than the one produced by non-methylated specific primers. d
Ectopic expression of RUNX1t1 in MKN28 and MKN45 gastric cancer
cell lines reduces gastric cancer cell proliferation as measured by BrdU
incorporation assay. S-phase percentages are indicated in the FACS plots
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may release C/EBPβ or inhibit its binding to DNA and thus
enhance TFF1 repression. In accordance with this notion,
MKN74 cells showed a dose-dependent increase in TFF1 ex-
pression after ectopic expression of RUNX1t1 (Fig. 5d).
Likewise, co-transfection of RUNX1t1 and C/EBPβ, together
with a TFF1 luciferase reporter abolished the repression of the
TFF1 promoter in the MKN45 by C/EBPβ (Fig. 5e).
Discussion
Comparison of gene expression profiles from C/EBPβ KO
mice and human gastric cancer samples provided an insight
in C/EBPβ-related molecular mechanisms. Taken together,
our data suggest a tumorigenic function of C/EBPβ in the
development of a subset of gastric tumors.
Data show that the function of C/EBPβ in gastric cancer is
embedded in the homeostatic regulation of the gastric mucosa.
Absence of C/EBPβ from the murine stomach shifts the bal-
ance from epithelial proliferation towards differentiation.
Although this was primarily observed in the thinner antral
epithelium, we do not exclude potential C/EBPβ-dependent
effects also in the proximal stomach, although they may be
more difficult to observe due to the more complex architecture
of the tissue. Deregulation of pathways that sustain C/EBPβ
functions, such as inflammatory signals, may enhance prolif-
eration and repression of differentiation genes, such as TFF1,
that ultimately promotes tumor development [11]. The data
also show that C/EBPβ is mandatory for the tumorigenic po-
tential of gastric cancer cell lines by promoting cell prolifera-
tion and confirm the repressive effect of C/EBPβ on the ex-
pression of TFF1.
Expression profiling data of human gastric cancer
samples and comparison with C/EBPβ KO mouse-
derived expression data identified a subset of tumors
with a C/EBPβ-regulated signature. These tumors most-
ly belong to the intestinal type or may define a novel
subtype. Despite the absence of TFF1 from the gene
list, one of the de-regulated cluster genes, RUNX1t1,
has previously been connected to both gastrointestinal
abnormalities [34] and to suppression of C/EBPβ func-
tions [33].
RUNX1t1, also known as MTG8 or ETO, is the recur-
rent t(8;21) translocation partner of the AML-ETO
Fig. 5 RUNX1t1 modulates C/EBPβ activity. a Immunostaining shows
C/EBPβ and RUNX1t1 colocalization in the neck zone of the normal
human gastric mucosa. b Flag-Immunoprecipitation after transfection of
gastric cell lines with a flag-tagged RUNX1t1 pulls down C/EBPβ.
Visible in the input Western blot is also that RUNX1t1 does not affect
C/EBPβ expression. c EMSA using a radiolabeled C/EBPβ consensus
probe shows that transfection of RUNX1t1 to gastric cancer cells reduces
the binding of C/EBPβ to DNA inMKN28 andMKN45 cell lines. Arrow
indicated the super-shift. Also visible in the control Western blots,
RUNX1t1 has no effect on basal C/EBPβ expression. d A RUNX1t1-
dependent increase in the expression of TFF1 was visible by real-time
PCR in the MKN74 cell line. e Luciferase assay in MKN45 cells
transfected with the TFF1-luciferase fused promoter shows that co-
transfection with RUNX1t1 reverts the repressive potential of C/EBPβ
on the TFF1 promoter
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(RUNX1/MTG8) fusion protein. AML-ETO accounts for
15 % of acute myeloid leukemia and 40 % of M2-type
leukemia, probably by interference with the differentiation
inducing functions of C/EBPα and PU.1 [35, 36].
RUNX1t1 is also a candidate tumor suppressor in ovarian
cancer [30] and loss of RUNX1t1 expression has been
associated with metastasis in pancreatic cancer [37].
Down-regulation of RUNX1t1 during homeostasis and
in intestinal-type gastric cancer may initially occur
through C/EBPβ; however, analysis of DNA methylation
showed that the RUNX1t1 promoter was frequently meth-
ylated in human gastric cancer samples. RUNX1t1 pro-
moter hypermethylation has also been observed in ovarian
cancer [30] and thus suggests an alternative route of
RUNX1t1 gene silencing in carcinogenesis.
Our data suggest that the RUNX1t1 tumor suppres-
sive function might be related to repression of C/EBPβ
DNA binding, reminiscent to its function in the
adipogenic clonal expansion phase that requires expres-
sion of C/EBPβ but also RUNX1t1 to prevent prema-
ture induction of C/EBPα and terminal fat cell differen-
tiation [33]. RUNX1t1 and C/EBPβ are both expressed
in the proliferative neck zone of the normal gastric mu-
cosa and, similar to adipogenesis, C/EBPβ is required
for proliferation and inhibition of differentiation genes
in this tissue. Thus, our data imply a regulatory loop
between C/EBPβ and RUNX1t1 in gastric mucosa, al-
though the detailed mechanism regulating the crosstalk
and molecular genetic interactions remains to be
addressed.
The connection between C/EBPβ and RUNX1t1 may
also be relevant in hematopoietic malignancies involving
the AML-ETO translocation product. Recently it has
been shown that RUNX1 and C/EBPβ mark all hema-
topoietic genes in embryonic stem cells during hemato-
poietic commitment [38]. It is thus tempting to specu-
late that the fusion of RUNX1 and RUNX1t1 in the
t(8;21) AML-ETO translocation may connect to early
commitment events that involve C/EBPβ. In any case,
we show that in gastric cancer development, high ex-
pression of C/EBPβ leads to reduction of RUNX1t1
expression and loss of RUNX1t1 may support unre-
strained C/EBPβ function and repression of differentia-
tion genes, including TFF1. Importantly, TFF1 deletion
has also been found to promote oncogenesis, suggesting
an important cross-regulation between C/EBPβ ,
RUNX1t1 and TFF1 [11].
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